Danaher Corp.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2358511028
USD
227.13
-1.33 (-0.58%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Danaher Corp. stock-summary
stock-summary
Danaher Corp.
Pharmaceuticals & Biotechnology
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through three segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification. Danaher's research and development, manufacturing, sales, distribution, service and administrative facilities were located in over 60 countries.
Company Coordinates stock-summary
Company Details
2200 Pennsylvania Ave NW Ste 800w , WASHINGTON DC : 20037-1731
stock-summary
Tel: 1 202 8280850
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 244 Schemes (34.6%)

Foreign Institutions

Held by 662 Foreign Institutions (20.97%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Steven Rales
Chairman of the Board
Mr. Rainer Blair
President, Chief Executive Officer, Director
Ms. Linda Hefner Filler
Lead Independent Director
Mr. Mitchell Rales
Director
Ms. Teri List-Stoll
Independent Director
Mr. Walter Lohr
Independent Director
Dr. Jessica Mega
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
5,936 Million
(Quarterly Results - Jun 2025)
Net Profit:
555 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 170,177 Million (Large Cap)

stock-summary
P/E

40.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.50%

stock-summary
Debt Equity

0.30

stock-summary
Return on Equity

8.10%

stock-summary
Price to Book

3.25